preventing/reversing resistance to herceptin

[SuzEQ]

It's not clear from this paper, or at least to me, if they are lumping newly diagnosed/early stage patients with metastatic patients in their statistics of Herceptin resistance. My understanding is there is a difference and there are other pathways at work in metastatic disease which leads to the resistance that are not operative in early stage disease .